Eli Lilly and Company (LLY) |
|
334.6 -1.53 (-0.46%)
|
03-27 16:03 |
|
Open: |
327.8 |
Pre. Close: |
336.13 |
|
High:
|
336.22 |
Low:
|
323.26 |
|
Volume:
|
3,102,236 |
Market Cap:
|
318,655(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:20:48 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 393.53 One year: 459.64 |
| Support: |
Support1: 319.79 Support2: 309.2 |
| Resistance: |
Resistance1: 336.92 Resistance2: 393.53 |
| Pivot: |
326.26  |
| Moving Average: |
MA(5): 333.11 MA(20): 323.58
MA(100): 348.04 MA(250): 326.88 |
| MACD: |
MACD(12,26): 0.8 Signal(9): -1.6 |
| Stochastic oscillator: |
%K(14,3): 92.6 %D(3): 89.1 |
| RSI: |
RSI(14): 57.1 |
| 52-week: |
High: 375.25 Low: 276.82 |
| Average Vol(K): |
3-Month: 3,128 (K) 10-Days: 3,698 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed below upper band by 23.9%. Bollinger Bands are 24.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
336.58 - 338.51 |
338.51 - 340.25 |
|
Low:
|
318.91 - 320.97 |
320.97 - 322.83 |
|
Close:
|
331.7 - 335.11 |
335.11 - 338.18 |
|
Company Description |
|
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. |
Headline News |
Mon, 27 Mar 2023
Eli Lilly & Co. stock falls Monday, underperforms market - MarketWatch
Mon, 27 Mar 2023
Novartis Stock Rockets As It Takes On Eli Lilly's Second Biggest ... - Investor's Business Daily
Mon, 27 Mar 2023
Bedrijfstakpensioenfonds Voor DE Media PNO Sells 11000 Shares ... - MarketBeat
Sat, 25 Mar 2023
Eli Lilly and Company (NYSE:LLY) Stake Boosted by Wesbanco ... - MarketBeat
Thu, 23 Mar 2023
Top Analyst Reports for Eli Lilly, Honeywell International & American ... - Nasdaq
Thu, 23 Mar 2023
Bank of Stockton Makes New Investment in Eli Lilly and Company ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
952 (M) |
| Shares Float |
899 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
84.3 (%) |
|
Shares Short
|
6,810 (K) |
|
Shares Short P.Month
|
4,930 (K) |
Stock Financials |
|
EPS
|
6.88 |
|
EPS Est Next Qtl
|
1.09 |
|
EPS Est This Year
|
4.19 |
|
EPS Est Next Year
|
4.63 |
|
Book Value (p.s.)
|
11.82 |
|
Profit Margin (%)
|
21.8 |
|
Operating Margin (%)
|
30.3 |
|
Return on Assets (ttm)
|
11 |
|
Return on Equity (ttm)
|
62.6 |
|
Qtrly Rev. Growth
|
-8.7 |
|
Gross Profit (p.s.)
|
23 |
|
Sales Per Share
|
29.96 |
|
EBITDA (p.s.)
|
10.68 |
|
Qtrly Earnings Growth
|
13 |
|
Operating Cash Flow
|
7,080 (M) |
|
Levered Free Cash Flow
|
5,490 (M) |
Stock Valuations |
|
PE Ratio
|
48.65 |
|
PEG Ratio
|
1.7 |
|
Price to Book value
|
28.29 |
|
Price to Sales
|
11.17 |
|
Price to Cash Flow
|
45.02 |
Stock Dividends |
|
Dividend
|
1.12 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.3% |
|
Dividend Pay Date
|
2022-03-09 |
|
Ex-Dividend Date
|
2022-02-13 |
|
Your Ad Here
|
|
